Weight loss drug reduced risk of COVID deaths in new study

A popular weight loss drug reduced the risk of COVID-19 deaths, according to a new study.

The research, published Friday in the Journal of the American College of Cardiology, found during a clinical trial of Wegovy that people taking the obesity drug during the COVID pandemic were less likely to die from the virus.

Semaglutide, the active medicine found in the drug, has become a popular option for people looking to lose weight. Wegovy has been widely used along with Ozempic ...